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Protective Immunity Against Cryptococcus
Neoformans Infection
Joel Schop*
ABSTRACT  Cryptococcus neoformans, the etiological agent of cryptococcosis, is an occasional
opportunistic fungal pathogen of immune competent individuals. However, it is a relatively frequent
cause of life-threatening meningoencephalitis and pulmonary infections in immunosuppressed hosts
and is a leading mycological cause of morbidity and mortality among patients with AIDS in most parts
of the world. The lack of an effective fungicidal regimen and the development of antifungal resistant
strains suggest that continued investigation is necessary to devise immunotherapeutic strategies, drug
targets and/or vaccines to combat C. neoformans infections.  Until recently, cryptococcal virulence
factors such as its polysaccharide capsule, macrophage parasitism, and its ability to induce an
ineffective antibody mediated immune (AMI) response along with a non-protective type II (Th2) cell-
mediated immune response have thwarted efforts to induce complete protective immunity against a
lethal cryptococcal strain in murine models. The presence of C. neoformans antibodies in adult human
serum suggests that immune competent individuals have difficulty resolving an early cryptococcal
infection allowing for the establishment of a subclinical chronic infection.  Recent studies have shown
that pro-inflammatory cytokines, specifically interferon-g (IFN-g), associated with type I (Th1) cell-
mediated immunity can successfully drive cell-mediated immune (CMI) responses to produce
protective immunity to a second experimental  C. neoformans infection in mice. This review will
evaluate the intricacies of the host-cryptococcal interaction and discuss recent developments in C.
neoformans research and the potential for human vaccines and/or drug therapies.
INTRODUCTION
Cryptococcus neoformans, the causative agent of
cryptococcosis, is a common encapsulated fungus that
can cause a range of illnesses from arthritis to prosthetic
valve implant infections and, most significantly, a lethal
infection of the central nervous system (CNS) leading
to meningoencephalitis, predominantly in
immunocompromised individuals (1, 2). With the
eruption of the HIV epidemic, C. neoformans has only
emerged as a serious human pathogen in the last 30
years and has become the leading mycological cause of
morbidity and mortality among AIDS patients (3, 4). It
is estimated that 6% to 10% of patients with AIDS in
the United States, Western Europe, and Australia and
0% to 50% of AIDS patients in sub-Saharan Africa
countries are infected with life-threatening cryptococcal
meningitis (5, 6). By the 1990s, C. neoformans had
become the leading cause of culture-positive meningitis
in many regions including New York City (7). 
Although this review will focus on cryptococcosis
which predominantly occurs in immunocompromised
individuals, increasing reports of CNS cryptococcosis
of immunocompetent, HIV-negative patients have been
described (8, 9). In a recent study, Ecevit  et al.
evaluated the poor prognosis of 9 non-
immunosuppressed patients with CNS cryptococcosis.
Seventy-seven percent of the individuals had no
underlying medical conditions and all 9 patients were
eventually treated with amphotericin B/azole therapy.
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The reported mortality rate was 44% while the rest
suffered neurological sequelae (9).
With amphotericin B/azole therapy and the advent of
highly active anti-retroviral therapy (HAART),
incidences of cryptococcosis have declined in HIV-
infected patients in the developed parts of the world
(10). However, the increase in HIV-negative,
immunocompetent patients receiving
immunosuppressive therapy, the large numbers of
people without economic access to HAART and the
high mortality and morbidity of HAART-related
immune reconstitution inflammatory syndrome (IRIS)
(11) begs the necessity for the development of a  C.
neoformans vaccine. This review will discuss the recent
progress in the understanding of cryptococcal-host
interactions and the challenges involved with the
development of protective immunity against  C.
neoformans.
THE FUNGUS AND VIRULENCE FACTORS
C. neoformans is usually found in yeast form, or oval
or spherical shape (Figure 1). Generally, the yeast form
reproduces by asexual budding, but sexual reproduction
has been observed with the formation of basidiospores -
sexual spores produced at the end of hyphae by
members of the phylum  Basidiomycota of which
Filobasidiella neoformans (the sexual state of  C.
neoformans) is a member. Until recently, C. neoformans
has been subdivided into two variants (var.),  C.
neoformans var. neoformans and  C. neoformans var.
gattii. However, a greater analysis of the genetic
structure of C. neoformans strains has resulted in the
elevation of C. neoformans var. gattii to species level
(12).  Cryptococcal isolates are also categorized
according to serotype based upon antigenic differences
in their polysaccharide capsules. Serotypes A, D, and
hybrid AD belong to C. neoformans and serotypes B
and C belong to C. gattii. C. neoformans serotype A
appears to be implicated in 99% of AIDS patients with
cryptococcosis worldwide, except France where
serotype A is responsible for around 80% of the
infections (13). More frequent cases of serotype D and
AD have been reported in Europe where cryptococcosis
is associated with 77% of HIV patients (14). Serotype A
contributes to 51% of C. neoformansinfection followed
by serotype D (30%) and serotype AD (19%) (14).
Given that C. neoformansserotype A still remains to be
the most prevalent variety amongst
immunocompromised individuals, we will confine the
majority of our discussion of cryptococcal immunity
and virulence characteristics to Cryptococcus.
C. neoformansSerotype A incorporates a multitude of
virulence factors to overcome host defenses, including
the ability to produce a variety of anti-oxidants.
Melanin is a free-radical scavenger that impedes
macrophage phagocytosis by helping to protect  C.
neoformans against nitrogen- and oxygen-derived
oxidants produced as defense mechanisms by the host
(15, 16, 17). Superoxide dismutase supplements
melanin by converting superoxide radicals into
hydrogen peroxide and molecular oxygen (18, 19).
Thioredoxin reductase and mannitol are also powerful
anti-oxidants produced by this fungal pathogen (20, 21).
Besides its resistance to oxidative stress,  C.
neoformans owes much of its uniqueness and
pathogenic virulence to its polysaccharide capsule. Not
only does the capsule provide a protective barrier
around the fungal cell wall but it also contains particular
capsular antigens, such as glucuronoxylomannan
(GXM), that have been suspected to elicit an adverse
immune response, allowing the microbe to escape
significant host phagocytosis and intercellular killing
(22, 23, 24).
Despite its virulence, a C. neoformans infection is
usually contained in immunocompetent hosts. Sera
studies suggest that the majority of the human
population is initially infected during early childhood
and repeatedly infected throughout life (25, 26).
Because of the rarity of clinical manifestation of
cryptococcosis in normal individuals, we can assume
that the host mounts an immune response that may not
completely eliminate the infection, but successfully
prevents disease. Therefore, a clinical cryptococcal
infection in humans, later in life, would more than likely
result from reactivation of a latent infection or an acute
re-infection in the contexts of an established chronic
infection.
HOST DEFENSE
Route of infection and innate immunity
Figure 1.  Scanning Electron Microscope (SEM) photo of
encapsulated pathogenic Cryptococcus neoformans yeast at a
magnification of x1,200. An acidic mucopolysaccharide
capsule completely encloses the fungus. C. neoformans
infection, cryptococcosis may lead to meningoencephalitis of
the central nervous system (CNS) predominantly in
immunocompromised humans with HIV/AIDS or undergoing
immunosuppressive therapy. Copyright Dennis Kunkel
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Although often overlooked, it is important to note
certain physical factors and barriers that impede the
establishment of  C. neoformans in the mammalian
environment. The initial defense to all fungal infections
is the skin. Since the skin provides an effective barrier
to  C. neoformans, the nasal and upper respiratory
airway openings appear to be critical host entry sites.
Kuttin et al. (27) have established that C. neoformans
has the ability to cross the mucosal and nasal epithelial
layers in mice and rats. The connection between the
nasal cavity and subcranial space suggests a possible C.
neoformans entry route into the central nervous system
(CNS). The degree to which this mode of passage
facilitates infection has yet to be defined.
It is commonly believed that inhalation is the primary
route of C. neoformans pulmonary infection in humans.
Considering C. neoformans grows less efficiently at the
human host temperature of 37°C than at its optimal
growth rate temperature of 25°C to 30°C (28), low
temperatures in the nasal passage might be
advantageous for fungal growth. 
Ciliary action and airway turbulence are generally
successful at preventing yeast cells from reaching the
alveoli, except the smaller basidiospores. Invasion of
the bronchial epithelium is sufficient to inflict direct
host damage and/or trigger an over-reactive
inflammatory response (29). For instance,  C.
neoformans var.  gatti has been associated with the
vigorous formation of granulomatous masses in the
lungs (30). A more severe systemic infection, mainly
seen in immunocompromised patients, can lead to C.
neoformans meningoencephalitis - a symptomatic




The complement system consists of a series of serum
proteins that are involved in non-specific host immune
responses. Complement proteins can be rapidly
activated to provide protection to the host via multiple
mechanisms including opsonization which promotes
phagocytosis of antigens, the lysis of foreign cells, and
the activation of inflammatory responses. Complement
system activation can occur via three pathways:
complement activation via the classical pathway is
initiated by the formation of antigen-antibody
complexes and requires specific antibody; activation of
the alternative pathway begins with binding of serum
proteins including the complement protein C3b to the
foreign cell surface and does not require the presence of
antibody;  lastly, the lectin pathway requires the binding
of lectins (proteins that bind specifically to
carbohydrate targets) to mannose residues on foreign
cells and, like the alternative pathway, does not require
specific antibodies.     
The level of complement cascade activation by  C.
neoformans surface antigens depends on the integrity of
its capsule and the presence of particular antifungal
antibodies in the host serum at the time of infection
(31). Although human serum contains sufficient
antibodies for  C. neoformans glucans, the
polysaccharide capsule blocks access to the yeast
surface (32). In naive host sera, there are insufficient
naturally occurring capsule-binding antibodies to
initiate the classical pathway (33). Therefore, the
alternative pathway remains the primary method for
activation of complement mediated phagocytosis of
encapsulated  C. neoformans. Immunofluorescence
studies have shown that the classical pathway results in
the immediate accumulation of C3 (a key complement
protein) on the cell surface, while the alternative
pathway activation lags behind 4 to 7 min before
significant C3 is present (33, 34). These findings
propose that the polysaccharide capsule is a key factor
in the ability of C. neoformans to slow the humoral
complement-mediated immune response.
Phagocytosis appears to be the primary method for
clearing C. neoformans infection. Various host defense
cells, employing a multitude of microbicidial
mechanisms, contribute to this process.
Polymorphonuclear (PMN) cells, also known as
neutrophils, are effective phagocytic cells in the early
stages of infection and may serve the immune system
best by containing a chronic  C. neoformans infection
(35). In a recent study, Marr K. et al. (36) explored the
similarities and differences of natural killer (NK) cells
anticryptococcal activity between humans and mice.
NK cells can play different roles in humans than in mice
during cryptococcal infection and vary in respect to
their distribution in the body, cytokine interaction,
receptor expression and their interaction with a variety
of other effecter molecules (36, 37). However,
macrophages undoubtedly play an essential role in C.
neoformans phagocytosis throughout the duration of the
infection in humans and mice. Macrophages are
professional phagocytic cells capable of ingesting
foreign cells via contact with antibody Fc receptors
and/or C3 receptors by means of the complement
pathways. Due to human host inefficiency to produce a
consistent amount of protective antibodies or the
inability to upregulate the necessary cytokines to elicit
an effective cell-mediated immune response,
macrophage phagocytosis mainly occurs via the
alternative complement pathway (34). 
During the immune response, macrophages and
human PMN cells produce an assortment of reactive
oxygen intermediates (ROIs) and nonoxidative
mechanisms that are capable of killing C. neoformans
(38, 39, 40). Human neutrophils produce hydrogen38 McGill Journal of Medicine 2007
peroxide (H2O2) which, in adequate amount is
fungicidal to  C. neoformans (39). Phagocytes also
produce non-oxidative antimicrobial proteins. Human
neutrophils contain defensins which can be extremely
lethal to  C. neoformans fungus (38). Murine
macrophages produce a histone-like microbicidial
protein which is also an effective cryptococcal killing
mechanism (40).
Although human phagocytes produce effective
antifungal molecules, many studies have shown that an
adequate cryptococcal defense involves macrophages
with sufficient stimulus to successfully phagocytosis
and kill  C. neoformans (41). Flesh  et al. (42)
demonstrated that murine (mouse) bone marrow
macrophages, in the presence of IFN-gamma and
bacterial lipopolysaccharide (LPS), can mount an
antifungal attack against C. neoformans in the absence
of complement and antibody opsonins. It has also been
shown that cytokines, specifically granulocyte-
macrophage colony-stimulating factors (GM-CSF) and
tumor necrosis factor-alpha (TNF-a) enhance
complement-mediated phagocytosis in vitro and in
murine models (43). Without these cytokines,
macrophages only ingested 1 to 2 cryptococcal cells  as
compared to 6 to 8 with appropriate cytokine
stimulation (43). Although a macrophage is fully
capable of  C. neoformans phagocytosis, this does not
necessary imply death of the fungus. C. neoformanshas
demonstrated the ability to survive and replicate within
macrophages in vitro and in vivo (44, 45, 46).
In summary, macrophages are proficient killers of C.
neoformans by phagocytosis, but are greatly dependent
on the presence of serum opsonins and cytokine-
mediated activation. The polysaccharide capsule
provides an effective barrier against complement-
mediated opsonization. Evidence points towards the
appropriate immune cytokine response as being a key




A correctly implemented immune response that
incorporates phagocytic killing mechanisms and the
appropriate memory T-cell and B-cell response is
required to mount an adequate immune defense against
C. neoformans. Fortunately, extensive study has been
conducted on antibody production to cryptococcal
polysaccharide antigens. However, not all  C.
neoformans antigens elicit protective antibody
production. The efficiency of an antibody-mediated
response is determined by monoclonal antibody (mAb)
isotype (having to do with Fc region: IgG, IgM, IgA,
IgE, IgD), epitope specificity (immunoglobulin hyper-
variable region specificity to C. neoformans antigens)
and affinity for different C. neoformans strains. The
antibody-mediated immunity (AMI) and the cell-
mediated immunity (CMI) responses to capsular
glucuronoxylomannan (GXM) sugars and cryptococcal
mannoproteins are the subject of the majority of
cryptococcal antigen studies to date.
Antibodies to C. neoformans polysaccharide capsule
are commonly found in immunocompetent individuals
with or without cryptococcal infection (26). Perhaps,
this antibody response is due to a past subclinical
infection (no manifestation of characteristic symptoms
of a C. neoformans infection) or a cross reaction with
other polysaccharides. Whatever the case, it is apparent
that immunocompetent individuals have some degree of
immunity to C. neoformans polysaccharide antigens.
GXM capsular sugars by themselves elicit very little
antibody immune responses and can wreak havoc on the
host immune system (47). However, when linked to a
protein carrier, such as tetanus toxoid (TT) or
Pseudomonas aeruginosa exoprotein A (rEPA), it
becomes highly immunogenic (48, 49). GXM
conjugated to tetanus toxoid (GXM-TT) has been
successful at providing partial protective antibody
production in only some mouse species (48). Not only
does this suggest that a GXM-TT protective immune
response depends on the host's genetic framework, but
studies have shown that GXM-TT was unsuccessful at
inducing partial protective immunity in mice with T-
cell, IFN-g, iNOS, B cells, and various other CMI
cytokine deficiencies (50). This is a significant
drawback considering that the majority of human
cryptococcal cases are those with HIV or
immunocompromised patients with low T-cell levels.
GXM-TT vaccine was proven to be immunogenic in
immunocompetent humans in a small clinical trial, but
its immunogenicity in immunocompromised individual
is still unclear (51).
This evidence suggests that a successful protective
AMI is greatly dependent on functional CMI and the
appropriate cytokine immune response. In the field of
cryptococcal research, it has generally been accepted
that C. neoformans capsular polysaccharides induce T-
cell-independent antibodies and, therefore, elicits a  Th2
immune response. In the above mentioned experiment,
it seems that the inactivation of T-cells and the lack of
Th1 cytokines, such as IFN-g, IL-12, and TNF-a, may
have interfered with the production of "protective"
antibodies.
Furthermore, disease-enhancing antibodies have been
described. The presence of too many antibodies of the
wrong type has been observed to produce
"immunological paralysis" or antibody
unresponsiveness (22, 51). Mice injected with more
than 100-400 µg of cryptococcal polysaccharide
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response as compared to mice injected with less than
100 µg (22). Apparently, the production of antibodies to
particular  C. neoformans capsular antigens can
"overload" the immune system. The effects of this
phenomena and the degree of T-cell involvement in this
response have not been thoroughly investigated in
humans.
In summary, AMI to  C. neoformans appears to be
complex. Convincing evidence supports the
interdependency of CMI and AMI in a successful host
defense response against C. neoformans. Considering
that immunocompetent individuals are capable of
producing only minimally protective antibodies to the
polysaccharide, the cooperation of the CMI and the
correct T-helper cell type cytokine response might be a
pivotal step to induce antibody-mediated protection.
The immunocompromised host's inability to mount an
effective AMI attack against C. neoformans infection
because of deficient or inappropriate T cell activation
also points to the importance of anti-cryptococcal CMI
responses.
Cell-Mediated Immunity
The foremost reasons to suspect significant T-cell
involvement in host immune response to C. neoformans
infection are 1) the difficultly of CMI deficient patients
to successfully mount an anti-cryptococcal immune
response, 2) the formation of granulomas usually
associated with extensive Th1 activation, 3) the
experimental evidence that naïve mice can adopt
protective immunity by T-cell transfer from immune
mice, and 4) successful stimulation of complete
acquired protective immunity in mice inoculated with a
C. neoformansstrain producing host IFN-g (3, 4, 30, 52,
53). Besides the fact that the T-helper cell plays the
central role in the specific immune response, as well as
the humoral response, and is essential for any successful
cryptococcal defense, many experiments provide
conclusive evidence that CMI is vital to the
development of protective immunity against  C.
neoformans.
Experiments have been performed with athymic mice
(nu/nu) that cannot efficiently facilitate a T-cell
mediated immune response. These mice were more
susceptible to the C. neoformans infection compared to
the control mice with a thymus (54). Moreover, athymic
mice were shown to be susceptible to chronic
cryptococcal infection when presented with an avirulent
nonencapsulated  C. neoformans strain (55). Upon
examination, nu/nu mice presented no granuloma
formation, less inflammatory evidence, and negative
delayed type hypersensitivity (DTH) responses (54, 56).
Similar studies of pulmonary infections in rats show
that C. neoformans in the lungs of nu/nu rats are lethal
(57). Normal rats can effectively clear a C. neoformans
pulmonary infection. This evidence suggests that
athymic mice and rats are unable to ward off a  C.
neoformans infection due to the lack of mature T-cells
in their serum.
Further studies implementing adoptive transfer
technique of mouse splenocytes have been performed to
analyze the potential for T-cell protective immunity
(52). After 35 days of cryptococcal infection, splenic T-
cells transferred to naïve mice produced a DTH reaction
and protective immunity when presented with  C.
neoformans (52). However, transfer of infected serum
did not confer significant immunity to the naïve host
(58). These studies seem to suggest that protective
immunity is possible in mice and is associated with T-
cells.
Wormley et al. (53, 58) have conducted 2 studies
analyzing the protective immune response to  C.
neoformans by way of Th1 cytokine responses in mice.
Over a period of 14 days, cytokine responses, CD4+
and CD8+ cell levels and pulmonary fungal burden
were recorded in mice challenged with known lethal C.
neoformans strain H99 and an avirulent temperature-
sensitive, calcineurin A1 (cna1) mutant strain (59).
Cna1 strains have been engineered to inefficiently
propagate a virulent infection in simulated host
environments (37ºC, 5% CO2, etc.) and have been
shown to be non-infectious in immunosuppressed
murine model studies (59). The mice presented with the
cna1 strains successfully resolved the infection while
mice challenged with the virulent strain all died within
a median of 16 days (58). However, the cna1 mice did
not demonstrate protection against a re-challenge with
pathogenic  C. neoformans strain H99 (58). When
inoculated with a second lethal C. neoformans strain,
the cna1 mice only survived approximately 17 days -
almost the same survival interval as the control group
inoculated with lethal C. neoformans H99 strain (58).
During the study, IL-4 levels increased in mice
inoculated with 106 CFU of cna1 mutant, indicative of
a Th2 response (58). In addition, IFN-gamma and IL-2
(Th1) cytokines levels did not significantly deviate
from the control norms in the cna1 mice as compared to
a serious, steady decline in mice inoculated with the
lethal strain (58). Considering the multitude of studies
showing the importance IFN-g in the development of
protective CMI to  C. neoformans, there is significant
evidence to conclude that cna1 inoculated mice failed to
produce substantial amounts of INF-gamma or initiate a
significant Th1 response to procure protection against a
secondary infection.
Knock-out (KO) studies by Hernandez et al. (60)
have also confirmed that a Th2 driven response
exacerbates C. neoformans infection. IL-4 KO and LI-
10 KO (cytokines affiliated with a Th2 response) mice40 McGill Journal of Medicine 2007
both resolved C. neoformans infection at a significantly
higher rate than wildtype C57BL/6 mice (60). In
contrast, treatment of cryptococcal resistant mice with
IL-4 and IL-10 increased fungal presence in the CNS
(61).
In light of these conclusions, follow-up studies by
Wormley et al. (53) focused on the activation of a Th1
response in murine models. They were able to transform
C. neoformans strain H99 with a construct allowing the
yeast to express low levels of the Th1-type cytokine
IFN-g.  The strain was designated C. neoformans strain
H99g (53). Besides its production of IFN-gamma, this
strain showed no signs of attenuated virulence when
compared to the known lethal, wildtype C. neoformans
strain H99 in vitro (53). When A/Jcr mice were given
intranasal inoculations of  C. neoformans strain H99g,
they were able to resolve a primary infection compared
to complete mortality for mice inoculated with the wild-
type strain (53).  Importantly, A/Jcr mice are deficient in
the complement protein C5a, a protein that is significant
in the recruitment of inflammatory cells during
inflammatory responses. The capacity of prior infection
with the IFN-g-producing strain to induce protective
anti-cryptococcal immunity in an "immune deficient"
mouse strain speaks very highly of the level of
protection that this strain generated against  C.
neoformans. To evaluate the possibility for acquired
protective immunity, immunocompetent BALB/c mice
that had resolved a previous primary infection with C.
neoformans strain H99g and mice that had survived a
primary infection with heat-killed C. neoformans strain
were both inoculated with a secondary infection of the
lethal wildtype C. neoformans strain H99. All mice that
had resolved a prior infection with the C. neoformans
strain H99g were able to survive a second cryptococcal
challenge with the pathogenic wild-type strain
demonstrating the development of complete protective
immunity as compared to 100% mortality of the mice
that had resolved the prior infection with heat-killed C.
neoformans (53). 
Cytokine and chemokine analysis revealed that
pulmonary levels of Th1 cytokines, IFN-g, IL-2, IL-12,
and TNF-a were substantially elevated as well as other
inflammatory cytokines and chemokines in H99g mice
(53). In contrast, the above mentioned cytokines and
chemokines levels were significantly lower in the wild-
type infected mice (53). However, wild-type infected
mice did show increased levels of Th2 cytokines, IL-4
and IL-5 as compared to the C. neoformansstrain H99g
immunized mice (53). These results suggest that
complete protective immunity is possible in mice when
a Th1 cytokine response is induced upon primary
infection with C. neoformans H99g strain.
In summary, 100% survival of a primary infection of
the  C. neoformans strain producing IFN-g and the
activation of protective immunity in mice is promising.
Experiments show that successful cryptococcal
protection is strongly connected to CMI, particularly the
activation of a Th1 response and Th1 cytokines, such as
IFN-g, IL-12, and TNF-a. Results showing that
susceptible mice naturally produce Th2 cytokines, with
a diminished Th1 response, when inoculated with a
pathogenic cryptococcal strain suggests that  C.
neoformans escapes destruction by mediating a biased
Th2 immune response (53, 58). It is possible to propose
that the human immune system suffers from the same
debilitating response to  C. neoformans and without
elevated Th1 cytokines, the AMI and Th2 response can
only produce partial protective immunity. Although this
response might be adequate in the immunocompetent
host, if this balance is tipped, as it is in patients
suffering from AIDS, the host defense against  C.
neoformans invasion could be severely impaired. The
process by which Th1 cytokine polarization stimulates
anti-cryptococcal protective immunity remains to be
thoroughly investigated.
MANNOPROTEINS
Host immune responses to cryptococcal proteins have
been associated with protection against experimental
infection in mice.  Vaccination of mice with a  C.
neoformans culture filtrate antigen (CneF) in complete
Freund's adjuvant (CFA) has been shown to induce
partial-protection against a subsequent cryptococcal
infection as well as to generate DTH responses (62).
Fractionation of CneF revealed its mannoproteins (MP)
fraction as the primary antigenic component responsible
for the stimulation of anti-cryptococcal CMI responses
in mice (62).  Subsequently, there has been great interest
in identifying the proteins that elicit protective host
responses to cryptococcal infection.  Mandel et al. (63)
have identified and cloned a gene, designated  DHA1,
which encodes a protein that induces DTH responses in
mice. Additionally, Biondo et al. (64) have described a
cryptococcal polysaccharide deacetylase that was used
as a vaccine strategy to prolong survival and decrease
fungal burden in mice. Levitz  et al. (65) have also
described a  C. neoformans mannoprotein, termed
MP98, which has molecular properties of a chitin
deacetylase and stimulates T cell responses to  C.
neoformans.  A second cryptococcal mannoprotein,
MP88, also identified by Levitz and collaborators was
also demonstrated to stimulate T cell responses (66).
More recently, two cryptococcal mannoproteins,
designated MP84 and MP115, were identified following
the reaction of various CneF mannoprotein fractions
with sera from patients and experimental animals with
cryptococcosis (67).
Current research suggests that mannoproteins activate
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presenting extensive o-mannosylated antigen to
macrophage mannose receptors (MMR) on the surface
of PMN cells, particularly dendritic cells (68, 69). The
antigen is endosytosed and released in to the endosome
to be processed for presentation on the major
histocompatibility complex class II (MHC class II) (68).
These antigen-presenting cells subsequently secrete IL-
12, generating Th1 cells and facilitating a
proinflammatory response with elevated IFN-?
production (70).  In vitro research involving human
monocytes and  in vivo murine studies have
demonstrated that IL-12 plays an essential role in the
development of a protective immune response (70, 71).
Pietrella et al. (72) also describe the stimulation of an
IFN-g and IL-12-directed Th1 protective response in
Candida albicans with cross-reactive MP from  C.
neoformans in mice and in vitro.
In summary, MPs, located in the  C. neoformans
envelope, are highly immunogenic and elicit DTH
responses along with a partially protective immune
response in mice (63, 71, 73). T-cell involvement and
increased secretion of IFN-g, TNF-a, IL-2 (75) and IL-
12 (70) have been associated with particular
mannoproteic determinants: MP98, MP88, MP84 and
MP115 (65, 66, 67). While it has been demonstrated
that purified capsular polysaccharides of C. neoformans
promotes IL-10 secretion, among other Th2 cytokines
that can downregulate proinflammatory Th1 cytokines
(74), MPs have been shown to shift the balance toward
a Th1 protective response. Although the value of these
cryptococcal proteins as vaccine candidates for the
prevention and/or treatment of C. neoformans infections
or relapses in immunosuppressed patients have yet to be
validated on a definitive basis, it appears that they have
the potential to be of benefit for the management of
cryptococcosis.
VACCINE STRATEGIES
As investigators get closer to discovering the
intricacies of the host immune response to  C.
neoformans infection, the possibilities of a vaccine
become more of a reality. It is promising to hear
evidence of cross-reactivity in Th1 responses to  C.
neoformans and the pathogenic fungus,  Candida
albicans (72). These conclusions imply the potential for
the first broad-spectrum vaccine that protects against
various pathogenic fungi. 
Development of a  C. neoformans strain capable of
producing host IFN-g is clearly a potential vaccine
strategy, but the form, method and efficiency of this
prospect in humans still needs to be investigated.
Furthermore, host defense to C. neoformans is complex
and probably entails an intricate collaboration of CMI,
AMI and innate immunity. A better understanding of the
Th1 response, how it can elicit protective immunity and
the role that AMI plays in this process must be devised
before a successful human vaccine candidate that
induces complete protective immunity can be
developed.
In addition to unanswered questions regarding anti-
cryptococcal host defense mechanisms, an incorrectly
polarized or severely impaired immune system is of
essential interest when discussing cryptococcal vaccine
strategies. Considering the majority of the  C.
neoformans clinical cases occur in
immunocompromised patients (5), the potential of
inciting an over-exuberant inflammatory response
(immune reconstitution) during latent C. neoformans
infection is a concern. This concern is apparent when
examining the host immune system's ability to self-
inflict damage during immune reconstitution
inflammatory syndrome (IRIS) in HIV patients treated
with HAART (11). Although studies with H99-g have
been shown to ramp up Th1 cells, which might suggest
a good strategy for AIDS and other
immunocompromised patients, it is unknown if such
methods will be successful in these populations.
CONCLUSION
With its polysaccharide capsule and its ability to evade
the bulk of immune defenses by driving a non-
protective Th2 response, C. neoformans has proven to
be one of the most challenging fungal infections of the
21st century. Microbiologists and immunologists
continue to decipher the cryptococcal code in order to
better understand its mechanisms of virulence. An AMI
response with antibody production from cryptococcal
antigen has only been demonstrated to elicit partial
protective immunity. New evidence points towards C.
neoformans interaction with the cell-mediated immune
system as being the basis by which  C. neoformans
infection is established. The conclusion that  C.
neoformans H99-g strain can induce primary immunity
in mice and elicit a complete secondary protective
immunity via induction of a CMI Th1 response may
prove crucial for the future of cryptococcal research.
Together with the discovery of cell surface
mannoproteins, there exists exciting potential for
human vaccine therapies that elicit a more appropriate
immune response to  C. neoformans infection. The
development of a cryptococcal fungal vaccine will,
undoubtedly, change the face of AIDS research and
offer a much better chance of survival for
immunocompromised patients and those undergoing
immunosuppressive therapies.
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